Free Access
| Issue |
Med Sci (Paris)
Volume 32, Novembre 2016
Les cahiers de myologie
|
|
|---|---|---|
| Page(s) | 57 - 59 | |
| Section | Clin d’oeil | |
| DOI | https://doi.org/10.1051/medsci/201632s217 | |
| Published online | 21 November 2016 | |
- Kaplan JC. DMD et saut d’exon thérapeutique : tout ce qu’il faut savoir en deux leçons. Les Cahiers de Myologie 2011 ; 5 : 46–47. [Google Scholar]
- Kaplan JC. DMD et saut d’exon thérapeutique. Leçon n° 2 : réalisation et perspectives. Les Cahiers de Myologie 2012 ; 6 : 45–46. [Google Scholar]
- Aartsma-Rus A, Van Ommen GJB. Antisense-mediated exon skipping: a versatile tool with therapeutic and research applications. RNA 2007 ; 13 : 1609–1624. [CrossRef] [PubMed] [Google Scholar]
- Van Putten MDWC, Heemskerk H, De Kimpe S, et al. Systemic delivery of antisense oligonucleotides restores dystrophin expression and functionality in the mdx mouse. Nice : Congrès AFM-Myologie, 2000, Poster PW26-322. [Google Scholar]
- Bilan de l’European Medicines Agency (EMA) établi en avril 2015. Antisense oligonucleotide-mediated exon skipping therapy development for Duchenne muscular dystrophy (DMD). http://exonskipping.eu/wp-content/uploads/2015/04/Briefing-Document-COST-and-SCOPE-DMD-EMA-meeting-April-2015-FINAL-VERSION.pdf [Google Scholar]
- Kaplan JC. L’enfer du génothérapeute est pavé de POC. Med Sci (Paris) 2015 ; 31 (hs3) : 41–44. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
- Voir l’historique sur le site de Drugs.com : Exondys 51 Approval History. https://www.drugs.com/history/exondys-51.html [Google Scholar]
- Voir https://www.drugs.com/newdrugs/fda-approves-exondys-51-eteplirsen-duchenne-muscular-dystrophy-4430.html [Google Scholar]
- Suivre la saga Sarepta sur StatNews : FDA panel votes against Sarepta’s drug for Duchenne muscular dystrophy. https://www.statnews.com/pharmalot/2016/04/25/fda-panel-sarepta-muscular-dystrophy/ [Google Scholar]
- Senators urge FDA to approve Sarepta drug for Duchenne - STAT https://www.statnews.com/pharmalot/2016/05/24/senators-urge-fda-approve-sarepta-drug-duchenne/ [Google Scholar]
- FDA confirms that critic of Sarepta drug has left the agency. https://www.statnews.com/pharmalot/2016/09/14/fda-sarepta-farkas-duchenne. [Google Scholar]
- FDA approves Sarepta’s controversial drug for Duchenne muscular dystrophy. https://www.statnews.com/pharmalot/2016/09/19/sarepta-wins-dmd-drug-approval/ [Google Scholar]
- Intense FDA bickering. https://www.statnews.com/pharmalot/2016/09/19/sarepta-fda-duchenne-behind-the-decision/ [Google Scholar]
- Tough as nails’: Storm swirls around FDA drug cop who approved controversial drug. https://www.statnews.com/2016/09/20/janet-woodcock-sarepta-fda/ [Google Scholar]
- Sarepta to charge $300K for Duchenne drug. We tried to be reasonable, CEO says. https://www.statnews.com/pharmalot/2016/09/19/sarepta-duchenne-drug-prices/ [Google Scholar]
- Did the FDA set ‘a dangerous precedent’ with its latest drug approval?. https://www.statnews.com/pharmalot/2016/09/19/fda-sarepta-precedent/ [Google Scholar]
- Voir le Communiqué de presse de Sarepta du 19/09/2016 : http://investorrelations.sarepta.com/phoenix.zhtml?c=64231&p=irol-newsArticle&ID=2204492. [Google Scholar]
- Voir l’article Eteplirsen sur wikipedia : https://en.wikipedia.org/wiki/Eteplirsen [Google Scholar]
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.